miRagen polycythemia vera drug receives orphan drug designation
Polycythemia vera is a myeloproliferative, potentially fatal disease which manifests itself in the form of an overabundance of blood cells and platelets in the body resulting in heart
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.